bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate · Monarch Pharms · NDA 050168, 050169, 050218, 050416, 050479

Cortisporin

Earliest generic entry, as listed · earliest of 4 marketed strengths
Open now

No marketed reference-listed strength; date taken from all listed strengths.

No unexpired patents or exclusivities are listed for this product.

Listed patents · 0 unexpired

No unexpired patents listed.

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

  • Generic approved · ANDA 220938, Orbicular Pharm Tech · 050479-001Approved 27 Aug 2026Detected 25 Oct 2026Historical import
  • Generic approved · ANDA 217803, Amneal · 050479-001Approved 29 Oct 2025Detected 25 Oct 2026Historical import

Products covered · 5

NDA · productFormStrengthListed expiry
050168 · 002 · RLD · discontinuedointment, topical400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**open
050169 · 001 · discontinuedsuspension/drops, ophthalmic1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLopen
050218 · 001 · RLD · discontinuedcream, topical0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**open
050416 · 002 · RLD · discontinuedointment, ophthalmic400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**open
050479 · 001 · RLD · discontinuedsolution/drops, otic1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**open